Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap

Merck has acquired Verona Pharma for $10 billion, primarily for its FDA-approved COPD drug Ohtuvayre, projected to achieve $4 billion in peak annual sales. This strategic acquisition aims to address the impending $15-20 billion Keytruda patent cliff in 2028, yet it is expected to cover only about 20% of the anticipated revenue decline. While part of Merck's broader diversification efforts, this deal underscores the significant challenge the company faces in fully offsetting Keytruda's eventual sales loss, leaving investors seeking more comprehensive solutions for sustained growth beyond 2028, contributing to Merck's recent stock underperformance.

Analysis

Merck's $10 billion acquisition of Verona Pharma for its FDA-approved COPD drug, Ohtuvayre, is a direct and aggressive move to mitigate the upcoming 2028 patent cliff for its blockbuster drug, Keytruda. However, the financial reality underscores the scale of the challenge: Ohtuvayre's projected $4 billion in peak annual sales is expected to cover only about 20% of the anticipated $15-20 billion revenue decline from Keytruda. This deal is consistent with Merck's recent strategy of deploying significant capital, including the $11.5 billion Acceleron purchase, but highlights that these actions are thus far only partial solutions. The market's reaction reflects this insufficiency, with Merck's stock (MRK) down 16% year-to-date, starkly underperforming the S&P 500's 7% gain and peers like Johnson & Johnson and AbbVie. This investor skepticism is further reflected in the company's valuation, which at approximately 11 times trailing earnings, is considerably below its historical average of 15 times. Until Merck can articulate a more comprehensive strategy that convinces investors it can both fill the revenue gap and generate new growth post-2028, its valuation is likely to remain under pressure, especially considering Keytruda accounts for nearly half of total sales.

Key Decisions for Investors

• Investors should recognize that the Verona Pharma acquisition, while strategically necessary, only partially addresses the looming Keytruda patent cliff, necessitating several more large-scale transactions or unexpectedly strong pipeline execution to fully bridge the revenue gap.
• The stock's suppressed valuation, trading at an 11x P/E ratio versus its historical 15x average, presents a potential value opportunity but is directly tied to significant execution risk; positions should be weighed against the lack of a clear growth trajectory post-2028.
• Closely monitor the progress of Merck's broader pipeline, with its 20 potential blockbusters, as successful clinical and commercial outcomes are now critical to shifting the negative investor sentiment driven by the Keytruda dependency.
• Given the stock's 16% year-to-date underperformance relative to the market and peers, investors should remain cautious until management provides a more convincing and complete strategy to offset the entirety of the Keytruda revenue loss.